Press Release

Tactical Therapeutics on WSJ

Special Biotechnology Report
24 June 2009,
Washington Post.

Click here to download the pdf

BIOWIRE 2K,
9 May 2006  ,
Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006

View more
 
Financing Sought

Private Funding by Angel Investors

 

Market

Angiogenesis inhibitors are expected to be used in the therapies of several different cancers-colon, breast, prostate, ovarian, head & neck/esophageal, pancreatic and lung among others.  CTO is a small molecule and it can be given orally. In addition, CTO is a synthetic oral inhibitor of calcium influx and has demonstrated anti-invasive and anti-proliferative properties. Most importantly, it will be cost effective in comparison to comparable biological angiogenesis inhibitors.

 

In Phase I CTO demonstrated activity in refractory tumors which were pretreated with targeted and non-targeted agents. Based on those results, CTO is being developed in several Phase II trials, ex. malignant ghomas and glioblastoma, ovarian cancer, non-small cell lung cancer, head, neck and metastatic colorectal cancer.

 

Copyright @ 2006, Tactical Therapeutics, Inc